- Regulatory authorities in Brazil signed off Clene Inc's (NASDAQ: CLNN) Phase 2 study evaluating CNM-ZnAg liquid solution in acutely symptomatic, non-hospitalized COVID-19 patients. CNM-ZnAg is a proprietary zinc-silver ionic solution.
- The 276-subject trial's primary endpoint will evaluate the rate of decreased hospitalizations at day 28, with secondary endpoints assessing time to symptom resolution.
- Enrollment will complete in mid-2021, with results expected in the second half of 2021.
- Price Action: CLNN gained 13.2% at $14.14 in market trading hours on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
